Journal of Thoracic Oncology (JTO), November 2020, Volume 15, Issue 11
Journal | English | 2020
Image For Activity Cover
Credit Offered
No Credit Offered
In This Issue
  • From the IASLC Tobacco Control Committee
  • A Call to Arms: Reducing Disparities in Lung Cancer Care Worldwide
  • Can We MIRror the Efficacy of Immune Checkpoints With miRNAs?
  • Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC
  • Immunotherapy and Coronavirus Disease 2019: Challenges and Possibilities
  • Improving Inequities in Lung Cancer Screening: Risk Prediction Models and the Potential to Achieve a Great Equalizer Effect
Editorial - Lung Cancer Worldwide
  • Lung Cancer in Thailand
Special Article - Statistics in Oncology Series
  • Guidelines for Statistical Reporting in Medical Journals
Review Article
  • Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury
Original Articles
  • Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities
  • Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance)
  • Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
Brief Reports
  • Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019–Infected Patients With Lung Cancer
  • Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC
Image of the Month
  • Two Sorts of Microthrombi in a Patient With Coronavirus Disease 2019 and Lung Cancer
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports
Powered By